Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Monday night, two groups of researchers released independent reviews of a back surgery device made by Medtronic, the $16 billion (sales) medical device giant. They found the product, Infuse, was no more effective than the older technique it was meant to replace and it carried added risks. Medtronic had commissioned the analyses itself. And their release is a landmark moment not just because of what they mean for a single product but because Medtronic gave outside researchers unprecedented access to its internal data, launching a new experiment in corporate transparency. If open science is to take flight in the traditionally secretive worlds of drug and medical device manufacturing, it may well look something like this, with small but independent groups being given access to deep dives into data.
Help employers find you! Check out all the jobs and post your resume.
